Clinical Trials Logo

Filter by:
NCT ID: NCT02462486 Completed - Clinical trials for Macular Degeneration

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Start date: June 25, 2015
Phase: Phase 3
Study type: Interventional

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

NCT ID: NCT02462044 Completed - Clinical trials for Coronary Artery Disease

Contrast Enhancement on Coronary Computed Tomographic Angiography

EICAR
Start date: August 2014
Phase: Phase 4
Study type: Interventional

Computed tomographic angiography (CTA) is an important prognostic tool with regard to the detection of coronary artery stenoses. Both iodine delivery rate (IDR; the amount of iodine delivered to the patient per second) and iodine concentration are decisive factors in the opacification of arterial vessels. There remains to be some debate in the literature about whether the use of high iodine concentration contrast media is beneficial compared to lower iodine concentrations. To date, there have not been any studies comparing intracoronary attenuation using concentrated contrast media lower than 300 mg I/ml at coronary CTA. For a reliable comparison of CM with different iodine concentrations, adapted injection protocols insuring an identical IDR (in g iodine per second) are mandatory. The investigators hypothesize that usage of lower iodine concentrations, while maintaining identical IDR and total iodine load, will result in comparable diagnostical intra-vascular attenuation in CTA.

NCT ID: NCT02461524 Terminated - Clinical trials for Abdominal Aortic Aneurysm

Endurant Evo International Clinical Trial

Start date: June 2015
Phase: N/A
Study type: Interventional

The purpose of this trial is to evaluate the safety and effectiveness of the Endurant Evo Abdominal Aortic Aneurysm (AAA) Stent graft system for endovascular treatment of subjects with infrarenal abdominal aortic or aortoiliac aneurysms.

NCT ID: NCT02460978 Completed - Clinical trials for Type 1 Diabetes Mellitus

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

DEPICT 2
Start date: July 8, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.

NCT ID: NCT02460965 Recruiting - Hallucinations Clinical Trials

Understanding Hallucinations (Part II)

UH-2
Start date: November 2013
Phase: N/A
Study type: Observational

Rationale: Hallucinations occur in many patients with different kinds of diseases, including psychiatric, neurological and perceptual impairment. The origin of these hallucinations is only partly understood. This prevents correct prediction of treatment response and hampers the development of new, more effective treatment strategies. Different subtypes of hallucinations resulting from different neuropathology may exist across diagnostic entities, and be responsive to different treatment strategies. Understanding the origin of these subtypes with use of fMRI and EEG can help to make rational treatment decisions on an individual basis and enhance the development of innovative treatment paradigms. Objective: The primary objective is to find specific abnormalities on resting state fMRI related to the pathophysiology of different subtypes of hallucinations. Secondary objectives are to find EEG connectivity measures that are related to the pathophysiology of different subtypes of hallucinations, reveal correlating patterns of EEG and fMRI that underlie the experience of hallucinations across different disorders, and to examine the frequency of spontaneous synchronized burst activations in auditory and visual cortices using fMRI. Study design: The investigators intend to examine neural correlates of hallucinations over different disorders using resting state EEG, fMRI and sMRI in an observational study. Study population: A total of 140 hallucinating patients will be included, 20 of each of the 7 different diagnostic groups. As a control group, 140 non-hallucinating patients with the same disorder of similar severity will be included. Main study parameters/endpoints: The main study endpoint is the difference in resting state correlates as measured with fMRI between hallucinating and non-hallucinating participants and between hallucinating individuals of different subtypes, namely: connectivity within the DMN and connectivity of the DMN to sensory cortices and the hippocampal-amygdala complex. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation in the study will entail an MRI scan of 40 minutes and an EEG measurement of 5 minutes. Total visit time, including preparations, will be approximately 2,5 hours. The risks associated with participation and the benefits to the individuals are negligible. The potential benefit to society in the future is considerable if the findings lead to optimization of treatment strategies and treatment response.

NCT ID: NCT02460458 Active, not recruiting - Clinical trials for Type 3 Von Willebrand's Disease

Type 3 Von Willebrand International Registries Inhibitor Prospective Study

3WINTERSIPSEXT
Start date: November 5, 2012
Phase:
Study type: Observational

International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor (VWF) concentrates used to treat VWD patients.

NCT ID: NCT02458638 Completed - Tumors Clinical Trials

A Study of Atezolizumab in Advanced Solid Tumors

Start date: July 16, 2015
Phase: Phase 2
Study type: Interventional

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

NCT ID: NCT02458560 Completed - Clinical trials for Aortic Valve Disease

CENTERA-2: Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve

Start date: March 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety and device success of the Edwards CENTERA Transcatheter Heart Valve (THV) System in symptomatic adult patients with severe aortic stenosis.

NCT ID: NCT02458417 Completed - Piebaldism Clinical Trials

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Start date: May 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of ReCell grafting after CO2 laser abrasion with superficial full surface ablation, fractional laser treatment and conventional (deep) full surface CO2 laser ablation, to assess the practical aspects and the patient reported outcome and to assess the cellular composition of the graft.

NCT ID: NCT02456740 Completed - Migraine Clinical Trials

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

STRIVE
Start date: July 17, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.